Suppr超能文献

当代背景下心力衰竭治疗中地高辛与收缩性心力衰竭患者的临床结局

Digoxin and clinical outcomes in systolic heart failure patients on contemporary background heart failure therapy.

作者信息

Dhaliwal Amandeep Singh, Bredikis Audrius, Habib Gabriel, Carabello Blase Anthony, Ramasubbu Kumudha, Bozkurt Biykem

机构信息

Section of Cardiology, Department of Medicine, Michael E DeBakey Veterans Affairs Medical Center, Houston, TX, USA.

出版信息

Am J Cardiol. 2008 Nov 15;102(10):1356-60. doi: 10.1016/j.amjcard.2008.07.014. Epub 2008 Sep 12.

Abstract

Previous trials have shown that digoxin was beneficial in patients with heart failure (HF). However, these studies were conducted before the incorporation of beta blockers as standard therapy for patients with HF. The purpose of this study was to determine the effect of digoxin in patients with HF on a contemporary regimen of renin-angiotensin inhibition and beta blockade. In 347 almost exclusively men, data pertaining to the index hospitalization and occurrence of all-cause mortality or readmission for HF were collected. Cox proportional hazard modeling was used. Patients on digoxin therapy had a lower left ventricular (LV) ejection fraction (EF), higher prevalence of previous hospitalizations for HF and atrial fibrillation, and lower prevalence of hypertension. After adjustment for age, LVEF, history of HF hospitalizations, New York Heart Association class, presence of chronic renal insufficiency, presence of atrial fibrillation, and prescriptions for beta blockers and angiotensin converting enzyme inhibitors or angiotensin receptor blockers, HF hospitalizations (hazard ratio 1.08, 95% confidence interval [CI] 0.77 to 1.50, p = 0.66), total mortality (hazard ratio 1.03, 95% CI 0.78 to 1.35, p = 0.85), or the combined end point of HF hospitalization and total mortality (hazard ratio 1.11, 95% CI 0.81 to 1.53, p = 0.52) were not different in patients using digoxin compared with those not using digoxin. Clinical outcomes were not different in subgroups of patients with EF < or =25%, New York Heart Association class III or IV, atrial fibrillation, heart rate < or =60 beats/min, or patients on beta-blocker therapy. In conclusion, digoxin use was not associated with a decrease in HF hospitalizations or overall mortality rates in a cohort of hospitalized patients with HF with LV systolic dysfunction on contemporary background HF treatment including angiotensin-converting enzyme inhibitors and beta blockers.

摘要

既往试验表明,地高辛对心力衰竭(HF)患者有益。然而,这些研究是在β受体阻滞剂被纳入HF患者的标准治疗之前进行的。本研究的目的是确定地高辛对采用当代肾素 - 血管紧张素抑制和β受体阻滞剂治疗方案的HF患者的影响。在347名几乎全为男性的患者中,收集了与本次住院以及全因死亡率或HF再入院发生率相关的数据。采用Cox比例风险模型。接受地高辛治疗的患者左心室(LV)射血分数(EF)较低,既往因HF和心房颤动住院的患病率较高,高血压患病率较低。在对年龄、LVEF、HF住院史、纽约心脏协会分级、慢性肾功能不全的存在、心房颤动的存在以及β受体阻滞剂和血管紧张素转换酶抑制剂或血管紧张素受体阻滞剂的处方进行调整后,与未使用地高辛的患者相比,使用地高辛的患者HF住院(风险比1.08,95%置信区间[CI]0.77至1.50,p = 0.66)、全因死亡率(风险比1.03,95%CI 0.78至1.35,p = 0.85)或HF住院和全因死亡率的联合终点(风险比1.11,95%CI 0.81至1.53,p = 0.52)并无差异。EF≤25%、纽约心脏协会III或IV级、心房颤动、心率≤60次/分钟的患者亚组或接受β受体阻滞剂治疗的患者,其临床结局并无差异。总之,在当代包括血管紧张素转换酶抑制剂和β受体阻滞剂的背景性HF治疗下,对于一组伴有LV收缩功能障碍的住院HF患者,使用地高辛与HF住院率或总体死亡率的降低无关。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验